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Abstract
Purpose: The objective was to investigate the dynamic enhancement patterns in focal solid liver lesions after the
administration of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) by means of dynamic
magnetic resonance imaging (MRI) including hepatobiliary phase (HP) images 20 min after Gd-EOB-DTPA administration.
Materials and Methods: Non-enhanced T1/T2-weighted as well as dynamic magnetic resonance (MR) images during the
arterial phase (AP), the portal venous phase (PVP), the late phase (LP), and the HP (20 min) were obtained from 83 patients
(54 male, 29 female, mean age 62.01 years) with focal solid liver lesions. MRI was conducted by means of a 1.5-T system for
63 patients with malignant liver lesions (HCCs: n = 34, metastases: n = 29) and for 20 patients with benign liver lesions (FNH
lesions: n = 14, hemangiomas: n = 3, adenomas: n = 3). For quantitative analysis, signal-to-noise ratios (SNR), contrast
enhancement ratios (CER), lesion-to-liver contrast ratios (LLC), and signal intensity (SI) ratios were measured.
Results: The SNR of liver parenchyma significantly increased in each dynamic phase after Gd-EOB-DTPA administration
compared to the SNR of non-enhanced images (p,0.001). The CER of HCCs and metastases significantly decreased between
LP and HP images (p = 0.0011, p,0.0001). However, FNH lesions did not show any significant difference, whereas an
increased CER was found in hemangiomas. The mean LLCs of FNH lesions were significantly higher than those of HCCs and
metastases. The LLC values of hemangiomas remained negative during the entire time course, whereas the LLC of
adenomas indicated hyperintensity from the AP to the LP. Furthermore, adenomas showed hypointensity in HP images.
Conclusion: Gd-EOB-DTPA-enhanced MRI may help diagnose focal solid liver lesions by evaluating their enhancement
patterns.
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Introduction
The detection and correct differentiation of focal solid liver
lesions still represents a challenge in daily clinical routine.
However, accurate diagnosis of such lesions is crucial for choosing
therapeutic approaches, tumor therapies, and surgical interven-
tions. Several trials have shown the superiority of magnetic
resonance imaging (MRI) to ultrasonography (US) and computed
tomography (CT) in both the detection and diagnosis of focal solid
liver lesions, and this superiority is mainly caused by the superior
soft tissue contrast of MRI [1,2]. Therefore, dynamic contrast-
enhanced MRI has been the method of choice for diagnosing focal
solid liver lesions [3–5]. Over the past few years, much effort has
been put into technical advances, such as improving software and
hardware, and into the development of new magnetic resonance
(MR) liver-specific contrast agents for improving the diagnostic
performance of MR liver images. The contrast agent Gadolinium
ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-
DTPA, gadoxetic acid disodium, Primovist, Schering, Berlin,
Germany) has only been recently introduced into clinical practice
for hepatic MRI examinations [6,7]. Gd-EOB-DTPA has
extracellular properties similar to that of conventional Gadoli-
num-containing extracellular MRI contrast agents. However, Gd-
EOB-DTPA has an additional property, i.e. an active ATP-
dependent hepatocyte uptake in which approximately 50% of the
injected dose is taken up via the organic anion transporter protein
1 (OATP1) and excreted by the biliary route [6,8]. Therefore, Gd-
EOB-DTPA combines the properties of initial tumor perfusion in
dynamic images and enhancement of delayed images in tumors
with a large blood pool or with hepatocytes maintaining cell
membrane function. Gd-EOB-DTPA-enhanced hepatobiliary
phase (HP) MRI has only recently been shown to facilitate the
differential diagnosis of hepatocellular lesions with and without
functioning bile ducts. Hepatocellular lesions with functioning bile
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ducts, such as focal nodular hyperplasia (FNH), exhibit iso- or
hyperintensity during the hepatobiliary phase, whereas hepatocel-
lular lesions without any bile ducts, such as adenomas (HCA) and
most hepatocellular carcinomas (HCC), lack enhancement in the
hepatobiliary phase [9–11]. However, these trials evaluated the
qualitative appearance of focal solid liver lesions during Gd-EOB-
DTPA-enhanced MRI. Moreover, only very limited data exist
both on the quantification of enhancement patterns of solid focal
liver lesions after the injection of Gd-EOB-DTPA as well as on the
potential to distinguish different lesions.
The purpose of this retrospective trial was to quantitatively
evaluate the enhancement patterns of solid focal liver lesions after
the administration of Gd-EOB-DTPA with the aim of differen-
tiating liver lesions according to their enhancement characteristics.
Materials and Methods
Patients
This retrospective trial was conducted from January 2009 to
September 2010 and included 83 patients with suspicious solid
focal liver lesions detected with US examinations or contrast-
enhanced CT. Patients underwent hepatic Gd-EOB-DTPA-
enhanced MRI to confirm or rule out malignancy. None of the
patients had any history of prior thermal ablation or chemother-
apy including transcatheter arterial chemoembolization (TACE).
None of the patients suffered from hemosiderosis or hemochro-
matosis because these conditions may possibly change the signal
intensity (SI) of the liver parenchyma due to iron deposition and a
consecutively altered liver-to-lesion contrast ratio (LLC). Our
study group comprised 54 men (mean age: 66.7; age range: 43 to
86 years) and 29 women (mean age: 53.3; age range: 21 to 83
years).
Ethics statement
The ethics committee of University of Regensburg confirmed,
that for this retrospective study without any study-related clinical
intervention or use of patients’ personal data no ethics-approval or
commission’s opinion was necessary. Patient information was
anonymized and de-identified prior to analysis.
Standard of reference
Lesions were considered benign (n= 20) if they did not show any
interval change of their size in the follow-up CT or MRI
examination after 6 months without treatment.
Diagnosis of malignant liver lesions was confirmed by means of
intraoperative findings and either consecutive histology (HCCs,
n = 5; metastases, n = 8), percutaneous needle biopsy (HCCs,
n = 24; metastases, n = 8), or surveillance by cross-sectional
imaging either with known primary tumor (metastases, n = 13)
or with pathologically elevated tumor marker (a-fetoprotein (AFP)
.196 ng/ml, HCC, n=5). 15 patients with HCC were diagnosed
with liver cirrhosis (Child Pugh A, n= 11; Child Pugh B, n= 3,
Child Pugh C, n= 1). Fig. 1 summarizes the means of confirming
the diagnosis of a liver lesion.
MR Imaging
Gadoxetic acid-enhanced MRI examinations were conducted
by means of a 1.5 T system (Magnetom Symphony, Siemens,
Erlangen, Germany) with the manufacturer’s body and spine array
coils. The entire liver was imaged in the transverse plane.
The pre-contrast protocol consisted of the following sequences:
respiratory-triggered single-shot T2-weighted turbo spin-echo
images (repetition time/echo time: 1000/85; slice thickness:
6 mm; matrix: 1806320; flip angle: 150u) followed by two
different breath-hold fast-spoiled gradient-echo images, i.e. T1-
weighted in-phase (repetition time/echo time: 87/4.8; slice
thickness: 6 mm; matrix: 1546320; flip angle: 60u) and T1-
weighted out-of-phase images (repetition time/echo time: 100/2.7;
slice thickness: 6 mm; matrix: 1546320; flip angle: 70u). Then, a
three-dimensional T1-weighted gradient-echo sequence was con-
ducted using the fat suppression technique (repetition time/echo
time: 4.0/1.5; slice thickness: 6 mm; matrix: 1746320; flip angle:
10u). After the administration of 10 ml Gd-EOB-DTPA with an
infusion rate of 3 mL/s via a 22-gauge intravenous cubital line
followed by a 15 mL saline-flush, the latter sequence was repeated
15 s, 60 s, and 120 s (dynamic phases) as well as 20 min after the
contrast injection to obtain dynamic contrast-enhanced MR
images. Also, respiratory-triggered T2-weighted turbo spin-echo
images with fat suppression (repetition time/echo time: 2220/79;
slice thickness: 6 mm; matrix: 3206320; flip angle: 140u) and
respiratory-triggered diffusion-weighted images (repetition time/
echo time: 1900/72; slice thickness: 6 mm; matrix: 1446192) were
obtained between the late phase (LP) after 120 s and the HP as
part of the routine liver MRI protocol.
Imaging analysis
For the image analysis, we used the commercially available
workstation of MRI scanner (Magnetom Symphony, Siemens,
Erlangen, Germany) and did the quantitative analysis of the
reference lesions with regard to the histology of tumor lesions,
laboratory results, patient histories, and the findings on previous
cross-sectional imaging in a blinded manner. SI of liver
parenchyma, reference focal solid liver lesions, and background
noise was measured in each patient for unenhanced T1-weighted
gradient-echo sequence, unenhanced respiratory-triggered single-
shot T2-weighted turbo spin-echo, and dynamic T1-weighted
gradient-echo sequences after 15 s during the arterial phase (AP),
after 60 s during the portal venous phase (PVP), after 120 s during
the LP, and after 20 min during the HP. Background noise was
defined as the standard deviation (SD) of the SI that was measured
in the air outside the body at the position of the intrahepatic region
of interest (ROI); thus, artifacts resulting from breathing and
vascular pulsing could be avoided. Comparable slice positions and
identical intra-axial positions were chosen. To measure SI of
normal liver parenchyma, ROIs were placed in such a manner
that blood vessels, necrotic areas, critical tissue, and artifacts were
avoided. For each sequence, ROIs in liver parenchyma and focal
solid liver lesions were drawn as large as possible (range: 0.7–
7 cm).
Signal-to-noise ratio (SNR) of the liver parenchyma was
calculated as SILV/SIA. SILV is the SI of the liver and SIA is the
standard deviation of the SI of the air used as a background noise.
LLC was calculated as follows: (SILE – SILVE)/SIA. SILE is SI of
the lesion on enhanced images, and SILVE is the SI of the liver on
enhanced images. Contrast enhancement ratios (CER) in focal
solid liver lesions were calculated as follows: (SILE - SILU)/SILU x
100, in which SILU represents the SI of the lesion on unenhanced
images. The SI ratio of each tumor in dynamic phase images was
also calculated as SILE/SILVE. All images were plotted over time,
and means and standard error of the mean (SEM) were recorded.
Statistical analysis
Data are presented in terms of relative frequencies. Inferential
statistics including mean value (6 SEM) and range were calculated
for SNR, LLC, CER, and SI ratios. In this quantitative analysis,
we tested the differences in SNR over time between all patients as
well as the differences in CER, LLC, and SI ratios between HCCs,
FNH lesions, and metastases on unenhanced, dynamic, and HP
Enhancement Patterns in Focal Solid Liver Lesions
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images with linear mixed models. The correlation structure over
time was specified as autoregressive, and the pair-wise post-hoc
comparisons were modified for multiplicity by means of Bonfer-
roni adjustments. All reported p-values are two-sided, and a P
value of 0.05 is considered to indicate a significant difference. All
analyses were conducted with SAS 9.3 and the linear mixed model
analyses with the procedure PROC MIXED. Descriptive statistics
for LLC, CER, and SI ratios over time were calculated for
hemangiomas and HCAs because of the small number of lesions.
Results
In contrast to the SNR of liver parenchyma of non-enhanced
images (71.863.4), the SNR significantly increased after Gd-EOB-
DTPA administration in all dynamic phases: in AP (79.764.0), in
PVP (101.465.5), in LP (108.065.7), and in HP images after
20 min (98.666.6) (p,0.0001) (Fig 2).
The mean CERs of the HCCs were 45.365.0, 54.865.5,
49.764.7, and 31.168.5 at 15 s, 60 s, 120 s, and 20 min after
contrast media injection. The CER did not significantly differ
between the dynamic AP to LP (p = 0.087-0.361), but a significant
difference in the CER was found between HP and PVP (p= 0.001)
and HP and LP (p = 0.0011).
The corresponding CERs of FNH lesions (82.368.1, 88.168.6,
83.866.1, and 79.867.8) showed no significant difference
between all dynamic phases over the time course (p = 0.472-
0.614). Liver metastases (29.164.5, 52.864.8, 55.264.4,
15.166.8) differed significantly with regard to the CER between
HP image and all dynamic phases over the time course (p#0.049-
0.001). The CER of adenomas (67.2621.8, 71.962.4, 63.165.1,
21.4613.0) showed a decrease in HP images, and the CER of
hemangiomas (6.766.5, 29.6615.5, 53.4626.2, 53.7626.4)
continuously increased over the time course of dynamic imaging.
The temporal CER of HCCs, metastases, FNH lesions,
adenoma and hemangioma at eachMRI phase are shown in Fig. 3.
On T2-weighted images, the mean LLC values of all liver
lesions were positive (HCCs 7.861.4, FNH lesions 4.661.5,
metastases 8.762.8, HCAs 13.761.4, hemangiomas 23.264.3).
Figure 1. Flowchart of patients and lesions. 83 consecutive patients were included in this trial. Malignant lesions (n = 63) were either
histologically proven (n = 45), or the diagnosis was based on AFP.196 ng/ml (n = 5) or on the knowledge of the primary tumor in case of metastases
(n = 13). Benign lesions (n = 20) did not show any change during the follow-up examinations over more than 6 months.
doi:10.1371/journal.pone.0100315.g001
Figure 2. Signal-to-noise ratios (SNRs) of liver parenchyma in
83 patients. In arterial phase images 15 s after Gd-EOB-DTPA
administration, a significant increase in SNR could be observed (mean
6 SEM, 71.863.4 vs. 79.763.4; p = 0.028). Furthermore, a significant
increase in SNR between 15 s and 60 s could be shown (mean 6 SEM,
79.763.4 vs. 101.465.5; p,0.0001). Over the further time course, no
other significant increase in SNR occurred (120 s, 108.065.7; 20 min,
98.666.6).
doi:10.1371/journal.pone.0100315.g002
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Fig. 4 shows the mean LLC values of all lesions on T1-weighted
images over the time course after contrast media injection.
On unenhanced T1-weighted images, the LLC values of both
HCCs and FNH lesions overlapped (p= 0.898). LCC values
significantly differed between HCCs and metastases (p = 0.001)
and between FNH lesions and metastases (p = 0.0151). With the
exception of adenomas (9.167.9), all liver lesions showed negative
LLC values on unenhanced T1-weighted images (HCCs, 2
4.263.2; FNH lesions, 24.962.1; metastases 218.462.3; hem-
angiomas, 219.862.7).
The mean LLC of FNH lesions during AP, PVP, LP, and HP
images (AP, 34.163.8; PVP, 8.963.2; LP, 10.563.3; HP 4.464.2)
were significantly higher than those of HCCs (AP; 11.263.6; PVP,
23.763.7; LP, 29.363.0; HP, 219.964.6; p#0.0202–0.001)
and metastases (AP, 212.562.8; PVP, 216.862.7; LP, 2
18.562.8; HP, 227.863.5; p,0.0001). The difference between
the lesion and the surrounding liver parenchyma was significantly
less for metastases than for HCCs (p#0.0315–0.001) in all imaging
phases except for the HP (p= 0.0684). The LLC of adenomas
showed positive values in the AP (33.8613.6), PVP (20.6610.3),
and LP (22.8611.4) and decreased in the HP, showing a negative
difference between the lesion and the surrounding liver parenchy-
ma. LLC values of hemangiomas remained negative over the
entire time course in the AP (220,2364.8), PVP (224,7163.2),
LP (223,8067.3), and the HP (217,8967.6), showing hypointens
lesions compared to the surrounding liver parenchyma.
In AP images, the SI ratio of FNH lesions (1.3860.05) was
significantly higher than that of HCCs (1.1960.06) and metastases
(0.8760.02) (p = 0.0017; p,0.0001). Each lesion showed signifi-
cantly decreased SI ratios (p,0.0001) in the HP images: FNH
lesions, 1.0560.03; HCCs, 0.860.04; metastases, 0.6960.02.
The mean SI ratio of adenomas indicated hyperintensity in AP
images and hypointensity in HP images, and the mean SI ratio of
hemangiomas showed hypointensity in both the AP and the HP
images.
A representative hepatobiliary phase image of each benign and
malignant liver lesion is shown in Fig. 5.
Figure 3. The graph shows the temporal mean contrast
enhancement ratios (CERs) of HCCs, metastases, adenomas,
hemangiomas, and FNH lesions at each MR imaging phase
during the arterial phase (15 s), the portal venous phase (60 s),
the late phase (120 s), and the hepatobiliary phase (20 min).
doi:10.1371/journal.pone.0100315.g003
Figure 4. The graph shows the temporal mean liver-to-lesion
contrast (LLC) ratios of HCCs, metastases, adenomas, heman-
giomas, and FNH lesions at each MR imaging phase in
unenhanced images, during the arterial phase (15 s), the
portal venous phase (60 s), the late phase (120 s), and the
hepatobiliary phase (20 min).
doi:10.1371/journal.pone.0100315.g004
Figure 5. Transverse 3D fat-suppressed T1- weighted gradient-
echo sequence obtained 20 min after Gd-EOB-DTPA adminis-
tration in hepatobiliary phase: white arrows depict (A)
hypointense HCC on cirrhotic liver parenchyma, (B) hypoin-
tense metastasis, (C) hypointense adenoma, (D) hypointense
hemangioma, (E) hyperintense FNH lesion with central scar.
doi:10.1371/journal.pone.0100315.g005
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Discussion
In clinical trials, liver-specific contrast media have been shown
to markedly improve the detection of focal solid liver lesions
[12,13]. However, with regard to a possible preoperative
evaluation of patients or the further management of patients after
lesion detection, the consecutive diagnosis of focal solid liver
lesions is of central importance in daily clinical routine. We
therefore evaluated enhancement patterns of focal solid liver
lesions in both dynamic phase and HP MR images; our images
constitute a representative collection of liver lesions in the clinical
routine of a university hospital.
Enhancement patterns of liver lesions during dynamic phases
after contrast media administration primarily depend on the
vascularity and blood supply of a tumor. However, enhancement
on delayed phase images is characterized by the cell specificity of
MR contrast agents. Gd-EOB-DTPA is a liver-specific, hepato-
biliary contrast agent that produces both dynamic perfusion and
liver-specific hepatobiliary MR images. This way, Gd-EOB-
DTPA combines the properties of an extracellular fluid contrast
agent, such as Gd-DTPA, and a hepatobiliary agent, such as Mn-
DPDP [14]. With regard to the detection and diagnosis of liver
lesions, at least equal results could be obtained with Gd-EOB-
DTPA and other extracellular contrast media in AP und PVP
images [13]. During hepatocyte selective phases, Gd-EOB-DTPA
is not only absorbed by normal liver parenchyma but also by focal
solid liver lesions of hepatocellular origin (HCAs, FNH lesions,
HCCs). The additional information provided by Gd-EOB-DTPA
in HP images can help distinguish hepatocyte-containing lesions
from non-hepatocyte-containing lesions [15,16].
In our study population consisting of patients with metastases,
benign liver lesions (FNH lesions, HCAs, hemangiomas), and
HCCs, we observed considerable enhancement of liver parenchy-
ma starting at 15 s after Gd-EOB-DTPA administration. Quan-
titative evaluation showed further significant enhancement of SNR
during PVP and LP that has also been shown in other clinical trials
[13] [17].
Comparing the SNR of patients with HCC (n=34) and the
SNR of patients with metastases and benign liver lesions (n = 49), a
diminished SNR could be shown in the AP images (HCCs,
68.666.1 vs. non-HCCs, 87.565.2) and the HP images (HCCs,
89.569.3 vs. non-HCCs, 104.969.1) of patients with HCC. The
transport of Gd-EOB-DTPA in hepatocytes is mediated by
OATP1 and multidrug resistance-associated protein 2 (MRP2),
and these two different transport systems are located at the
sinusoidal and canalicular membranes of the cell [18]. Our
findings support the results of other trials that showed delayed
uptake of Gd-EOB-DTPA in patients with progressively impaired
hepatic function, for example, in patients with liver fibrosis [19].
Decreased enhancement of cirrhotic liver parenchyma after Gd-
EOB-DTPA administration has only recently been shown to be
attributed to lower OATP1-activity, along with the slower contrast
media hepatocyte uptake and the rapid elimination of Gd-EOB-
DTPA due to up-regulated MRP2 activity [20].
Consistent to established imaging findings with Gd-EOB-DTPA
and non-specific extracellular contrast media, HCCs in our trial
became hyperintens with hyperenhancement in the AP after 15 s
[13,21,22]. Over the further time course, we observed progres-
sively negative differences between HCCs and the surrounding
liver parenchyma during the PVP, the LP, and the HP with a most
markedly negative contrast (washout) in the HP.
It has been shown that HCCs appear hypointens in HP
images – most likely due to the down-regulation of OATP1 and
the increased expression of MRP2 –, even though they lack the
characteristic enhancement features of HCCs in early dynamic
phases, for instance, due to the persistent portal venous blood
supply in early HCC [23,24]. Thus, Gd-EOB-DTPA might help
differentiate small HCCs from dysplastic nodules and pseudovas-
cular lesions, which do not commonly show hypointensity during
the HP [25,26]. In our trial, however, 8 HCCs appeared isointens
to hyperintens in relation to the surrounding liver parenchyma,
most likely because of the high MRP2 expression in the canalicular
membrane and the down-regulation of MRP2 in the luminal
membrane [27].
The CER of HCCs did not significantly change during the
dynamic phases; however, the contrast enhancement significantly
decreased during the HP, again emphasizing the added value of
the HP in terms of characterizing HCCs.
Liver metastases appeared hyperintens on T2-weighted images
and hypointens on unenhanced and dynamic phase images in
relation to the surrounding liver parenchyma with a significant
decrease of LLC between the dynamic LP and HP. FNH lesions
and hepatic adenomas are focal solid liver lesions of hepatocellular
origin, and a known characteristic feature of these lesions is the
arterial enhancement during dynamic imaging [1,28]. The correct
differentiation of FNH lesions and hepatic adenomas is of great
clinical relevance and has always been a challenge, because
adenomas hold the possibility for malignant transformation and
may cause severe complications, such as hemorrhage due to
rupture of the adenoma [29].
FNH lesions, which typically appear as a solitary lesion in young
women, are considered to consist of aggregated hepatocytes in
terms of a proliferative response of liver parenchymal cells to a
preexisting vascular malformation along with malformed biliary
ducts [30]. It is therefore reasonable to assume that the presence of
disordered vascular structures and malformed biliary ducts may
lead to prominent arterial enhancement and to reduced biliary
excretion of contrast media, resulting in signal hyperintensity
during HP imaging. We observed strong arterial enhancement of
all FNH lesions (100%) in AP images, and 7 FNH lesions (57.1%)
were markedly hyperintens in relation to the surrounding liver
parenchyma during the HP.
Hepatic adenoma, however, contain well-differentiated monot-
onous hepatocytes that are separated by dilated sinusoids lacking
biliary elements or portal tracks and are normally surrounded by a
stromal capsule [31]. In our trial, arterial enhancement was
weaker in hepatic adenomas than in FNH lesions, most likely
because of a dilutive effect of the contrast media in dilated
sinusoids. Similar to FNH lesions, adenomas appeared hyperintens
in AP, PVP, and LP images, impeding the differentiation between
these two lesions. During the HP, however, adenomas appeared
hypointens in comparison to the adjacent liver parenchyma. This
finding supports other trials postulating that HP imaging may help
differentiate FNH lesions and adenomas [10,32,33]. However,
published data on enhancement patterns of hepatic adenomas
with Gd-EOB-DTPA-enhanced HP MRI are very limited and do
vary. To the best of our knowledge, only four trials exist describing
the behavior of histologically proven adenomas in delayed Gd-
EOB-DTPA-enhanced imaging: all adenomas described by
Giovanoli et al. (3 adenomas) and Mohajer et al. (6 adenomas)
showed hypointensity in HP imaging; out of the 3 adenomas
investigated by Huppertz et al., 1 was hypointens, and 2 were
hyperintens. In 2012, Grazioli et al. described 43 adenomas of
which 40 showed hypointensity and only 3 hyperintensity during
HP imaging, most likely owing to severe hepatic steatosis [9,34-
36]. Both the absence of biliary ductules and the altered expression
of the uptake transporter organic anion transporting polypeptide
Enhancement Patterns in Focal Solid Liver Lesions
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(OATP 8) in adenomas may explain the lack of contrast uptake in
HP images [6_ENREF_6,32].
Our trial has several limitations. First, we did not take a needle
biopsy of every hepatic nodule. The majority of HCCs and
metastases were proven by histology, diagnosed according to
surgical findings or results of percutaneous biopsies. Because, in
most cases, diagnosis of a benign liver lesion may lead to
conservative management, FNH lesions, HCAs, and hemangio-
mas were not histologically confirmed. All benign lesions had
remained unchanged at the follow-up examinations after more
than 6 months without treatment.
Second, the low number of benign liver lesions in our trial
necessitates further trials with a higher number of patients.
Furthermore, Gd-EOB-DTPA-enhanced MRI was conducted
regardless of the liver function; delayed hepatocyte uptake concurs
with diminished liver function, which might have influenced the SI
of a lesion, particularly in case of HCC in cirrhosis.
Accepting these limitations we conclude that the clinical
usefulness of Gd-EOB-DTPA is based on analyzing the biphasic
enhancement characteristics of liver parenchyma and focal solid
liver lesions during both the dynamic perfusion phases and the
HP. Furthermore, Gd-EOB-DTPA-enhanced MRI may help
diagnose focal solid liver lesions by evaluating their enhancement
patterns.
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